Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AmericaFirst Defensive Growth Fund Class I (DGQIX)

Net Asset Value
1 Day
Overall Morningstar Rating
Long-short equity
Style or Category
No Load
Sales Expenses
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks to achieve capital appreciation through all market cycles. The fund seeks to achieve its investment objective by investing- under normal circumstances- a range of approximately 70% to 100% of its net assets in a portfolio of defensive- non-cyclical equity securities of foreign and domestic companies selected by applying a rules-based strategy. Equity securities include common stock. The fund may target having approximately 0% to 30% of its assets in short positions under normal market conditions.


1 month0.00% 3 years-1.90%
3 months+1.56% 5 years+4.10%
1 year+6.15% Since inception+5.45%
Data through --

Peer Comparisonvs. Long-short equity

Performance 5-yr return+4.10%+6.23%
Expense ratio2.74%1.90%
Risk 5 year sharpe ratio0.500.79
Net assets$20.3M$316.4M
Average market cap$27.2B$40.8B
Average P/E20.617.0
Portfolio turnover341%341%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyAmericaFirst Funds
Fund manager & tenureRick Gonsalves / 6 Years
Minimal initial investment$1,000,000.00
Minimum IRA investment--


U.S. stock95.03%
International stock0.00%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
SYY Sysco Corp4.99%
EXC Exelon3.87%
IGT International Game Technology PLC3.13%
A Agilent Technologies Inc2.83%
TMO Thermo Fisher Scientific Inc2.83%
SID Companhia Siderurgica Nacional2.75%
PG Procter & Gamble2.75%
BAX Baxter International Inc2.70%
STZ Constellation Brands Inc2.69%
BMRN Biomarin Pharmaceutical Inc2.67%